• news.cision.com/
  • Phase Holographic/
  • Phase Holographic Imaging provides second HoloMonitor® to University of California, San Francisco to accelerate skin cancer research

Phase Holographic Imaging provides second HoloMonitor® to University of California, San Francisco to accelerate skin cancer research

Report this content

Phase Holographic Imaging (PHI) has entered into a collaboration agreement with University of California, San Francisco (UCSF) to accelerate ongoing skin cancer research at UCSF. Under the 11 month agreement, PHI will provide a HoloMonitor® M4.5 with a motorized stage to supplement the instrument which UCSF purchased previously for preclinical research in the field.

“A key strategic goal for the US market is to establish HoloMonitor technology through Centers of Excellence in the Boston, San Diego and San Francisco areas. With its five Nobel laureates, UCSF is widely regarded as one of the world's leading universities in health sciences. The collaboration with UCSF is an exciting step towards establishing a Center of Excellence in the San Francisco area”, says CEO Peter Egelberg.

Centers of Excellence
The purpose of PHI’s Centers of Excellence program is to create industry visibility in life science hotspots such as London, Basel, Heidelberg, San Diego, San Francisco, Boston and Tokyo. A Center of Excellence is an application development hub and educational resource providing training programs for scientists using PHI’s HoloMonitor technology. A first Center of Excellence has been established at Northeastern University in Boston.

Links

For additional information, please contact:
Peter Egelberg, CEO
Tel: +46 703 19 42 74
E-mail: peter.egelberg@phiab.se
Web: www.phiab.se

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

UC Disclaimer
The information stated above was prepared by Phase Holographic Imaging (PHI) and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of PHI, or any of its products, by The Regents of the University of California, its officers, agents and employees.

Subscribe

Documents & Links